PharmaLectures.com

Courses › Pharma industry foundations › The signature that stops a batch: what the Qualified Person actually does

The signature that stops a batch: what the Qualified Person actually does

Your Qualified Person signs on the first read, and the batch ships on time.

A Qualified Person pharma means the named individual, required by Articles 48 to 52 of Directive 2001/83/EC, who must certify every batch of a medicinal product before it is released for sale in the European Union. The QP confirms that the batch was made and tested in line with the marketing authorisation and GMP, and signs a register that an inspector can open at any time. Annex 16 of the EU GMP guide sets out how that certification works, including how a QP may rely on audits, agreements and confirmations from other sites, which is exactly where a supplier outside Europe enters the picture.

  • 6 audio modulesthree lengths each
  • 1 h to 5 hbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Management, QA, BDwho it is written for

Why Qualified Person pharma training matters

A finished batch waits in quarantine because one deviation has no sign-off in the batch record. The Qualified Person will not certify, the delivery date slips, and the customer calls. Then the inspector asks why release needs so much rework.

What changes after this course

Your team hands over batch files that answer the Qualified Person's questions before they are asked. Release becomes routine, not a Friday negotiation. You hold a certificate for each learner and a training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

Qualified Person pharma training: what this course gives your people

Your quality team stops guessing what the Qualified Person needs. A batch file reaches the desk with the deviation assessed, the signatures in place and the answer to the Annex 16 question already written. The back-and-forth emails stop, and the batch leaves quarantine on the day you planned. Directive 2001/83/EC no longer feels like something only legal can read.

Contract manufacturers stop being a source of audit findings. When a supplier sends a report, your staff check it against Chapter 7 of the European Union Good Manufacturing Practice guide and spot missing analytical data early. Chapter 1 on the Pharmaceutical Quality System gives them the frame to record what they found and who decided.

A pallet from outside the European Union arrives and nobody has to ask what paperwork is missing. Your team knows which retesting Article 51 asks for and when an agreement with the exporting country removes it. Release stops waiting on a search through old emails.

On the day a borderline deviation threatens the month's output, you bring one page built on International Council for Harmonisation Q9. It states the risk, the evidence and the proposed decision. The Qualified Person can sign or hold, and either way the decision stands when an inspector reads it later.

Who needs Qualified Person pharma training

  • Quality Assurance Manager

    Your reviewers spend days chasing a missing deviation sign-off. After this course your staff catch it before the file reaches the Qualified Person, and the review ends on the first read.

  • Head of Regulatory Affairs

    An inspector asks how release matches the dossier. You answer from a file that already shows the link between the batch, the marketing authorisation and the Qualified Person's certificate.

  • Supply Chain Director

    A third-country shipment sits in the warehouse waiting for release. Your team knows which documents and tests the Qualified Person needs, so the pallets stop waiting on paperwork.

  • Business Development Manager

    A customer asks if your contract manufacturer can support their launch. You answer from a Chapter 7 view of who certifies, who audits and who is responsible, before you promise a date.

  • Operations Director

    A borderline deviation threatens the month's output. You bring the Qualified Person a one-page risk assessment instead of a plea, and you get a clear sign or hold.

Roles: Owner, CEO and board, Business development and export sales, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: India, China, Türkiye, Korea, Japan, Taiwan, Egypt, Gulf and MENA, Brazil and Latin America, Pakistan, Bangladesh and Vietnam, United States, Europe

Selling into: any jurisdiction

Courses are in English. Other languages on request.

After this course your people can

  1. Name the legal duties of the Qualified Person under Article 51 of Directive 2001/83/EC and say which of them depend on your team.
  2. Check a batch file against the Annex 16 certification requirements and mark every gap before it reaches the Qualified Person.
  3. Write a deviation report that gives the certifier the cause, the impact and the decision without a follow-up question.
  4. Review a contract manufacturer against Chapter 7 of the European Union Good Manufacturing Practice guide and record the result.
  5. List the documents and tests required to release a batch imported from a third country.
  6. Apply International Council for Harmonisation Q9 to a borderline batch and present the result on one page.
  7. Report a rejection decision to senior management in writing, with the reasons and the next step.

What the company gets

  • Batches leave quarantine sooner because your staff submit complete files that pass the Qualified Person's review on the first read.
  • Your contract manufacturing oversight is documented against Chapter 7, so an inspector's question about responsibility meets a written answer.
  • Imported medicinal products move to release without a hunt for missing documents or test results.
  • Management gets a straight, written reason when a batch is held or rejected, instead of a late phone call.
  • You hold a certificate and a training record for each learner, ready to show an inspector.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 6 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard2 h 30 min25 min a module, for regulatory, quality and business-development staff
Expanded5 h50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Owner, CEO and boardBriefing1 h
Business development and export salesBriefing1 h
Quality assurance and Qualified PersonStandard2 h 30 min

Qualified Person pharma course outline: 6 modules

6 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Name the legal duties of your Qualified Person under Directive 2001/83/EC

    • Why the Qualified Person answers personally for each batch, and what that makes them ask of you.
    • The duties that Article 51 of Directive 2001/83/EC puts on one named person, not on your department.
    • How to answer in one email the questions your certifier would otherwise raise in a meeting.
  2. 2Apply Good Manufacturing Practice rules to release batches without rework

    • What to do when a deviation lands the day before release and the file shows no assessment.
    • The Good Manufacturing Practice rules that decide whether your certifier signs or holds.
    • How to write a deviation report that closes the question instead of opening three more.
  3. 3Close the contract manufacturing gaps that threaten your supply chain

    • How to audit a contract manufacturer so your Qualified Person can rely on the result under Annex 16.
    • The written contract terms under Chapter 7 that settle who does what when a batch goes wrong.
    • What an inspector reads in your supplier qualification file, and how to have it ready.
  4. 4Assemble the batch file your Qualified Person can certify the same day

    • How to build a batch file that answers each question before your certifier asks it.
    • The documentation errors that send a batch file back, and the check that catches them first.
    • What a batch certificate commits the Qualified Person to, so you stop sending thin files.
  5. 5Clear the regulatory hurdles for importing medicinal products

    • How to tell which imported batches need full testing in the European Union and which do not.
    • The checks on imported batches that Article 51 requires before a Qualified Person can certify.
    • When the paperwork for a parallel import differs from a third-country import, and what to prepare.
  6. 6Justify hard batch release decisions with a risk-based approach

    • How to apply International Council for Harmonisation Q9 to a borderline batch in one page.
    • What to say to senior management when the answer is reject, and how to put it in writing.
    • When quality risk management supports release and when it only hides a problem you must hold.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about Qualified Person pharma training

What is a Qualified Person in the pharmaceutical industry?

A Qualified Person is a legally defined role in the European Union, held by someone with the education and experience listed in Article 49 of Directive 2001/83/EC and named on a manufacturing or import authorisation. The QP is personally responsible for certifying that each batch complies with the marketing authorisation and GMP before release, and can refuse to certify a batch regardless of commercial pressure.

What is QP release?

QP release usually means QP certification, the step where the Qualified Person records in a register that a batch meets the requirements, which must happen before the batch is released for sale. Before signing, the QP needs evidence that manufacture and testing met the authorisation, that deviations and changes were closed, that the supply chain is traceable, and that imported batches were retested or covered by a mutual recognition agreement. Nothing ships in Europe without that signature.

What does Annex 16 require?

Annex 16, in force since April 2016, describes the certification process: what the QP must personally verify, what may be relied upon from other QPs or audited third parties under written agreements, how the supply chain for the active substance and excipients must be documented, how unexpected deviations are handled, and the content of the QP register. It also lets a QP rely on audits of a supplier, which is why your audit history matters to European customers.

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

6 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h in the briefing length and 5 h in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Management, QA, BD. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team